Craft

Seikagaku

Stock Price

¥853

2024-10-29

Market Capitalization

¥46.6 B

2024-10-29

Revenue

¥39.4 B

FY, 2025

Seikagaku Summary

Company Summary

Overview
Seikagaku is a company that manufactures and sells pharmaceuticals and medical devices related to glycoconjugates. It operates within two segments: a Pharmaceutical and a LAL business. The Pharmaceutical segment is engaged in the manufacture of pharmaceuticals and medical devices with glycoconjugates, specifically, glycosaminoglycans (GAG) such as hyaluronic acid as well as enzymes that act on GAG. The LAL segment is dedicated to the manufacture and commercializing of endotoxin-detecting reagents, made from limulus amebocyte lysate, that are used to test for endotoxins in pharmaceuticals and medical devices.
Type
Public
Status
Active
Founded
1947
HQ
Tokyo, JP | view all locations
Website
https://www.seikagaku.co.jp/ja/index.html
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Ken Mizutani, President & CEO, Director

    • Toshiyuki Okada

      Toshiyuki Okada, Executive Vice President, Reliability Assurance, Director

    • Yosuke Funakoshi, Executive Vice President, Research & Development, Director

      • Mio Minaki, Outside Director

        LocationsView all

        4 locations detected

        • Tokyo, Tokyo HQ

          Japan

          Marunouchi Center Building 10fl. 6-1, Marunouchi 1-chome

        • Higashiyamato, Tokyo

          Japan

          1253, Tateno 3-chome

        • Takahagi, Ibaraki

          Japan

          258-5, Aza-Matsukubo, Oaza-Akahama

        • Yokosuka, Kanagawa

          Japan

          3-1, Kurihama 9-chome

        Seikagaku Financials

        Summary Financials

        Revenue (H1, 2026)
        ¥17.9B
        Gross profit (H1, 2026)
        ¥8.3B
        Net income (H1, 2026)
        ¥229.0M
        Cash (H1, 2026)
        ¥9.1B
        EBIT (H1, 2026)
        (¥619.0M)
        Enterprise value
        $37.9B

        Footer menu